CureVac disappoints in COVID vaccine trial

After a slew of wildly successful vaccine trials, this week marked a more underwhelming result. The third mRNA vaccine to complete phase three trials, developed by CureVac, is just 47% effective at staving off disease according to preliminary data. This is a stark contrast with previous mRNA vaccines from Moderna and Pfizer BioNtec which returned around twice that efficacy in their trials. In this episode of Coronapod, we ask why the CureVac vaccine has faltered, and what this might mean for the future of the pandemic and mRNA vaccine development.


News: CureVac COVID vaccine let-down spotlights mRNA design challenges

News Feature: How COVID unlocked the power of RNA vaccines


Subscribe to Nature Briefing, an unmissable daily round-up of science news, opinion and analysis free in your inbox every weekday.


 

See acast.com/privacy for privacy and opt-out information.